Specifically, programs of research for the quantification of tau positivity in early and advanced cases of AD need to receive immediate attention as resulting evidence would potentially guide proper scanning protocols, the validation of visual reading guidelines, and improved estimation of tau load as a function of disease. The gene discussed is MAPT; the disease is Alzheimer disease.